"Incidence of Major Adverse Cardiovascular and/or Limb Events among Patients Using Aspirin for Secondary Prevention"

Patients with coronary artery disease (CAD) and peripheral artery disease (PAD) are at elevated risk for build-up...

[1]  B. Nordestgaard,et al.  Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention. , 2020, JAMA cardiology.

[2]  Deepak L. Bhatt,et al.  External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry , 2018, European heart journal.

[3]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[4]  J. Berger,et al.  Underuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease. , 2017, Journal of the American College of Cardiology.

[5]  M. Stuntz,et al.  Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012–2015☆ , 2016, Preventive medicine reports.

[6]  J. Johnston,et al.  A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results , 2015, Trials.

[7]  Mary G. George,et al.  Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012). , 2015, The American journal of cardiology.

[8]  R. Ferrari,et al.  Management of outpatients in France with stable coronary artery disease. Findings from the prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease (CLARIFY) registry. , 2014, Archives of cardiovascular diseases.

[9]  John Spertus,et al.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. , 2011, Circulation.

[10]  J. Beckman,et al.  Secondary Prevention and Mortality in Peripheral Artery Disease: National Health and Nutrition Examination Study, 1999 to 2004 , 2011, Circulation.

[11]  Deepak L. Bhatt,et al.  Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.

[12]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[13]  K. Knopf,et al.  Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. , 2006, Clinical colorectal cancer.

[14]  Deepak L. Bhatt,et al.  The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. , 2006, American heart journal.

[15]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[16]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[17]  J. Bosch,et al.  Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2018, Lancet.